scholarly journals Naringenin Inhibits Proliferation and Survival of Tamoxifen‐ Resistant Breast Cancer Cells

10.5772/66698 ◽  
2017 ◽  
Author(s):  
Joseph Ramos ◽  
Talia Hatkevich ◽  
Lauren Eanes ◽  
Idalys Santos-Sanchez ◽  
Yashomati M. Patel
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistant

scholarly journals Differential effect of EGFR inhibitors on tamoxifen-resistant breast cancer cells

2015 ◽  
Vol 34 (3) ◽  
pp. 1613-1619 ◽  
Author(s):  
SANGMIN KIM ◽  
JEONGMIN LEE ◽  
SOO JIN OH ◽  
SEOK JIN NAM ◽  
JEONG EON LEE
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Differential Effect ◽  
Breast Cancer Cells ◽  
Egfr Inhibitors ◽  
Tamoxifen Resistant

scholarly journals Activated Farnesoid X Receptor inhibits growth of tamoxifen‐resistant breast cancer cells.

2010 ◽  
Vol 24 (S1) ◽  
Author(s):  
Cinzia Giordano ◽  
Donatella Vizza ◽  
Salvatore Panza ◽  
Ines Barone ◽  
Daniela Bonofiglio ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Farnesoid X Receptor ◽  
Tamoxifen Resistant

scholarly journals Poly-ADP-Ribosylation of Estrogen Receptor-Alpha by PARP1 Mediates Antiestrogen Resistance in Human Breast Cancer Cells

Cancers ◽  
2019 ◽  
Vol 11 (1) ◽  
pp. 43 ◽  
Author(s):  
Nicholas Pulliam ◽  
Jessica Tang ◽  
Weini Wang ◽  
Fang Fang ◽  
Riddhi Sood ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Oxidative Stress ◽  
Estrogen Receptor ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Target Genes ◽  
Tamoxifen Resistance ◽  
Tamoxifen Treatment ◽  
Dependent Manner ◽  
Tamoxifen Resistant

Therapeutic targeting of estrogen receptor-α (ERα) by the anti-estrogen tamoxifen is standard of care for premenopausal breast cancer patients and remains a key component of treatment strategies for postmenopausal patients. While tamoxifen significantly increases overall survival, tamoxifen resistance remains a major limitation despite continued expression of ERα in resistant tumors. Previous reports have described increased oxidative stress in tamoxifen resistant versus sensitive breast cancer and a role for PARP1 in mediating oxidative damage repair. We hypothesized that PARP1 activity mediated tamoxifen resistance in ERα-positive breast cancer and that combining the antiestrogen tamoxifen with a PARP1 inhibitor (PARPi) would sensitize tamoxifen resistant cells to tamoxifen therapy. In tamoxifen-resistant vs. -sensitive breast cancer cells, oxidative stress and PARP1 overexpression were increased. Furthermore, differential PARylation of ERα was observed in tamoxifen-resistant versus -sensitive cells, and ERα PARylation was increased by tamoxifen treatment. Loss of ERα PARylation following treatment with a PARP inhibitor (talazoparib) augmented tamoxifen sensitivity and decreased localization of both ERα and PARP1 to ERα-target genes. Co-administration of talazoparib plus tamoxifen increased DNA damage accumulation and decreased cell survival in a dose-dependent manner. The ability of PARPi to overcome tamoxifen resistance was dependent on ERα, as lack of ERα-mediated estrogen signaling expression and showed no response to tamoxifen-PARPi treatment. These results correlate ERα PARylation with tamoxifen resistance and indicate a novel mechanism-based approach to overcome tamoxifen resistance in ER+ breast cancer.

Activation of mitogenic pathways and sensitization to estrogen-induced apoptosis: two independent characteristics of tamoxifen-resistant breast cancer cells?

2006 ◽  
Vol 100 (1) ◽  
pp. 1-11 ◽  
Author(s):  
Alexander M. Scherbakov ◽  
Yulia S. Lobanova ◽  
Valentina A. Shatskaya ◽  
Oksana V. Onopchenko ◽  
Elena S. Gershtein ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Cancer Cells ◽  
Breast Cancer Cells ◽  
Tamoxifen Resistant ◽  
Induced Apoptosis
Sign in / Sign up

Export Citation Format

Share Document